Differentiating the VHA from Other Integrated Delivery Networks
Despite tremendous business opportunity, pharma and biotech manufacturers struggle to optimize positioning in the Veterans Health Administration (VHA). Our team seeks to help our industry partners understand how to be effective in this market and how it differs from other integrated delivery networks.
Here are 3 considerations unique to the VHA that pharmaceutical manufacturers should consider when planning their market access strategy:
- The VHA may not formally review newly approved drugs on a required review cycle, but instead conducts reviews based on its own unique patient populations and drug management needs. A manufacturer can help educate the VHA on the importance of establishing a smooth pathway to a new therapy for the appropriate patient.
- The VHA has established and maintains 10 oncology pathways to date that guide treatment as appropriate for veterans needing a wide range of cancer treatment evidence.
- The VHA offers incredibly unique and exciting contracting opportunities including “winner takes all” 1:1 national contracts and innovative value-based agreements.
We can help you prepare for your conversations with the VHA. We leverage our deep VHA experience to guide our pharma clients through the regimented process with ease. Click here to contact us and discuss how we can partner with you to craft a strong VHA access strategy.